Bristol-Myers Squibb Company (BMY - Analyst Report) is a major producer and distributor of pharmaceuticals and other healthcare related products. New York-based Bristol-Myers manufactures and sells branded pharmaceutical drugs such as Baraclude for hepatitis B virus (HBV), Sustiva for HIV and Erbitux for cancer.

However, like many of its peers, Bristol-Myers is facing generic competition for several of the important products. Moreover, its hepatitis C franchise may suffer a setback due to entry of newer therapies in this market.

In this scenario, investor focus remains on company’s high-profile immuno-oncology candidate, Opdivo and the newly-approved cocktail therapy, Daklinza plus Sunvepra, for treating chronic HCV.

Bristol-Myers has a pretty good earnings track record with the company delivering positive earnings surprises in all of the last four quarters with an average surprise of 18.96%.

Currently, Bristol-Myers has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings : Bristol-Myers beat on earnings by a wide margin. Our consensus called for EPS of 34 cents, and the company reported EPS of 53 cents.

Revenue : Revenues also above expectations. Bristol-Myers posted revenues of $4.2 billion, compared to our consensus estimate of $3.7 billion.

Key Stats : Once again, Bristol-Myers has topped our estimates driven by strong sales of drugs targeting the oncology market. The company also raised its 2015 earnings guidance. Bristol-Myers expects adjusted earnings per share in the range of $1.70 to $1.80 per share as compared to previous guidance of $1.60 to $1.70. The pre-earnings Zacks Consensus Estimate of $1.73 is within the guided range.